glaucoma_net_ru
Ассоциации
facebook
АйНьюс.РФ
eye5
Шахматы
профессор
Beaver
Конгресс
medlab
YouTube
Mobile
appstore
Торика
askin_heid
www.worldglaucoma.org
Конгресс 2014
varthamana2
Конгресс
Первая пятница декабря
Основные мероприятия ассоциации офтальмологов
bannerparasol
Флаги
santen
oftalmolog_club
ВК
Главная / Новости / Проленса! Prolensa!
год назад
10 марта 2016

Проленса! Prolensa!

IMPORTANT SAFETY INFORMATION ABOUT PROLENSA

  • PROLENSA contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

  • All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

  • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs.

  • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.

  • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.

     

    читать далее на http://www.bausch.com/ecp/our-products/rx-pharmaceuticals/rx-pharmaceuticals/prolensa-bromfenac-ophthalmic-solution 

Голосование
Что "заставляет" Вас заниматься научными исследованиями?